Fig. 3From: Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)Overall survival (left) and progression-free survival (right) by A sBCMA decline, B transgene persistence, and C ADA. 280 days is the median Tlast value for the patient population. ADA antidrug antibody, BL baseline, sBCMA soluble B cell maturation antigen, Tlast last time point of detectable transgeneBack to article page